JP6605020B2 - Ｎｒ２ｂ受容体阻害剤としてのトリアゾール - Google Patents

Ｎｒ２ｂ受容体阻害剤としてのトリアゾール Download PDF

Info

Publication number
JP6605020B2
JP6605020B2 JP2017508504A JP2017508504A JP6605020B2 JP 6605020 B2 JP6605020 B2 JP 6605020B2 JP 2017508504 A JP2017508504 A JP 2017508504A JP 2017508504 A JP2017508504 A JP 2017508504A JP 6605020 B2 JP6605020 B2 JP 6605020B2
Authority
JP
Japan
Prior art keywords
phenyl
triazole
ylmethyl
imidazol
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017508504A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524019A5 (enExample
JP2017524019A (ja
Inventor
シンドラー，ルドルフ
ランカウ，ハンス−ヨカキム
ホーゲン，ノルベルト
エグルランド，ウテ
ランゲン，バーバラ
ドスト，リタ
ワード，シモン
Original Assignee
ヤンセン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカルズ，インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2017524019A publication Critical patent/JP2017524019A/ja
Publication of JP2017524019A5 publication Critical patent/JP2017524019A5/ja
Application granted granted Critical
Publication of JP6605020B2 publication Critical patent/JP6605020B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017508504A 2014-08-15 2015-08-14 Ｎｒ２ｂ受容体阻害剤としてのトリアゾール Active JP6605020B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462037831P 2014-08-15 2014-08-15
US62/037,831 2014-08-15
US201562146656P 2015-04-13 2015-04-13
US62/146,656 2015-04-13
PCT/US2015/045412 WO2016025917A1 (en) 2014-08-15 2015-08-14 Triazoles as nr2b receptor inhibitors

Publications (3)

Publication Number Publication Date
JP2017524019A JP2017524019A (ja) 2017-08-24
JP2017524019A5 JP2017524019A5 (enExample) 2018-09-20
JP6605020B2 true JP6605020B2 (ja) 2019-11-13

Family

ID=54266608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017508504A Active JP6605020B2 (ja) 2014-08-15 2015-08-14 Ｎｒ２ｂ受容体阻害剤としてのトリアゾール

Country Status (9)

Country Link
US (2) US9981950B2 (enExample)
EP (1) EP3180329B1 (enExample)
JP (1) JP6605020B2 (enExample)
DK (1) DK3180329T3 (enExample)
ES (1) ES2791186T3 (enExample)
HU (1) HUE049277T2 (enExample)
PL (1) PL3180329T3 (enExample)
PT (1) PT3180329T (enExample)
WO (1) WO2016025917A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6605020B2 (ja) 2014-08-15 2019-11-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｎｒ２ｂ受容体阻害剤としてのトリアゾール
WO2016025918A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Pyrazoles
BR112018000468A2 (pt) 2015-07-09 2018-09-18 Janssen Pharmaceutica Nv 4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b
JP6923543B2 (ja) 2016-02-10 2021-08-18 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｒ２ｂ選択的ｎｍｄａ調節因子としての置換１，２，３−トリアゾール
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
WO2018111008A1 (ko) 2016-12-14 2018-06-21 에스케이바이오팜 주식회사 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
US11008302B2 (en) 2018-04-04 2021-05-18 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
BR112021023562A2 (pt) 2019-06-14 2022-01-04 Janssen Pharmaceutica Nv Carbamatos de pirazina e seus usos como moduladores do receptor de glun2b
US11161846B2 (en) 2019-06-14 2021-11-02 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators
BR112021025141A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
WO2020249792A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
CA3143105A1 (en) 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610723B2 (en) * 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
US7534800B2 (en) 2002-03-28 2009-05-19 Eisai R & D Development Co., Ltd. 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
JP2007523178A (ja) 2004-02-18 2007-08-16 アストラゼネカ アクチボラグ 代謝型グルタメート受容体アンタゴニストとしてのトリアゾール化合物およびそれらの使用
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
MX2009012749A (es) 2007-05-25 2010-03-10 Abbott Gmbh & Co Kg Compuestos heterociclicos como moduladores positivos del receptor de glutamato metabotropico 2 (receptor mglu2).
CN101842357A (zh) 2007-08-30 2010-09-22 武田药品工业株式会社 取代的吡唑衍生物
WO2009058261A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation of sleep with nr2b receptor antagonists
NZ588698A (en) * 2008-03-27 2012-06-29 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
ES2459047T3 (es) 2008-08-05 2014-05-07 Daiichi Sankyo Company, Limited Derivados de imidazopiridin-2-ona
US9643922B2 (en) * 2008-08-18 2017-05-09 Yale University MIF modulators
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
EP3037421A3 (en) 2008-11-25 2016-11-30 University Of Rochester Mlk inhibitors and methods of use
EP2408753A4 (en) * 2009-03-20 2012-11-07 Univ Brandeis COMPOUNDS AND METHOD FOR THE TREATMENT OF MICROBIAL STOMACH DARM INFECTIONS IN MAMMALS
WO2011156245A2 (en) 2010-06-09 2011-12-15 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
WO2014124651A1 (en) 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
JP2016516710A (ja) 2013-03-13 2016-06-09 アッヴィ・インコーポレイテッド ピリジン系ｃｄｋ９キナーゼ阻害薬
WO2016025918A1 (en) 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Pyrazoles
JP6605020B2 (ja) 2014-08-15 2019-11-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド Ｎｒ２ｂ受容体阻害剤としてのトリアゾール
BR112018000468A2 (pt) 2015-07-09 2018-09-18 Janssen Pharmaceutica Nv 4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b
JP6923543B2 (ja) 2016-02-10 2021-08-18 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｒ２ｂ選択的ｎｍｄａ調節因子としての置換１，２，３−トリアゾール
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途

Also Published As

Publication number Publication date
EP3180329B1 (en) 2020-03-18
PT3180329T (pt) 2020-06-08
US10323021B2 (en) 2019-06-18
EP3180329A1 (en) 2017-06-21
WO2016025917A1 (en) 2016-02-18
US20170226087A1 (en) 2017-08-10
HUE049277T2 (hu) 2020-09-28
JP2017524019A (ja) 2017-08-24
US20180282305A1 (en) 2018-10-04
DK3180329T3 (da) 2020-04-06
US9981950B2 (en) 2018-05-29
PL3180329T3 (pl) 2020-08-24
ES2791186T3 (es) 2020-11-03

Similar Documents

Publication Publication Date Title
JP6605020B2 (ja) Ｎｒ２ｂ受容体阻害剤としてのトリアゾール
JP6618525B2 (ja) ピラゾール類
US8110588B2 (en) 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
JP5726737B2 (ja) 自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体
KR20130119970A (ko) 신규 헤테로시클릭 유도체 및 신경계 장애의 치료에서의 그의 용도
CN110234638B (zh) 杂芳基苯氧基苯甲酰胺kappa阿片类配体
TW200911254A (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842
JP2014532066A (ja) オキサジン誘導体および神経障害の処置におけるその使用
JP2009538866A (ja) 新規１，４−ジアザ−ビシクロ［３．２．２］ノニルオキサジアゾリル誘導体及びそれらの医学的使用
US10280159B2 (en) Fused (hetero)cyclic compounds as S1P modulators
US11345666B2 (en) Phenyl and pyridinyl substituted imidazoles as modulators of RORγT
JP2013513615A (ja) 脂肪酸アミドヒドロラーゼのアゾ環状阻害薬
MX2011001070A (es) Nuevos derivados de difenil 1,2,3-triazol utiles como moduladores de los receptores de acetilcolina nicotinicos.
WO2016067143A1 (en) N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
JP2007517855A (ja) セロトニン及びノルアドレナリン再取込み阻害剤としての活性を示すピペラジン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191015

R150 Certificate of patent or registration of utility model

Ref document number: 6605020

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250